Skip to main content
SpringerLink
Log in

Passive and Active Targeting of Brain Tumors

  • Protocol
  • First Online:
Nanotherapy for Brain Tumor Drug Delivery

Part of the book series: Neuromethods ((NM,volume 163))

  • 488 Accesses

Abstract

Delivery of the pharmaceutically active agents towards the central nervous system (CNS) is usually challenging due to the presence of the blood-brain barrier (BBB). Brain tumors, compared to other types of CNS diseases and other types of tumors, remain difficult to treat with very little improvement in the survival rate in the last decades (Huse JT, Holland EC, Nat Rev Cancer 10:319, 2010). In this case, it is not only required to deliver a chemotherapeutic through the BBB to the brain but also to deliver it selectively to the tumor site rather than the healthy brain tissues. Nonselective distribution of the chemotherapeutics usually causes severe side effects that limit the efficiency of the treatment. This chapter summarizes some selected recent methods to prepare carrier systems capable of both efficient delivery through the BBB and active or passive targeting of the tumors within the brain tissues. This includes the description of methods to prepare the carrier systems along with the needed characterization techniques as well as in vitro and in vivo testing of its efficiency. Additional aim of this chapter is to provide the basic knowledge and skills needed for preparation of such systems and discusses the potentials or limitations of the described systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y (2003) Primary brain tumours in adults. Lancet 361:323–331

    Article  Google Scholar 

  2. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319

    Article  CAS  Google Scholar 

  3. Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  Google Scholar 

  4. Libermann TA, Nusbaum HR, Razon N et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144

    Article  CAS  Google Scholar 

  5. Henson JW, Schnitker BL, Correa KM et al (1994) The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36:714–721

    Article  CAS  Google Scholar 

  6. Clarke ID, Dirks PB (2003) A human brain tumor-derived PDGFR-α deletion mutant is transforming. Oncogene 22:722

    Article  CAS  Google Scholar 

  7. Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 7:436–451

    Article  CAS  Google Scholar 

  8. Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648–677

    Article  CAS  Google Scholar 

  9. Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207–217

    Article  CAS  Google Scholar 

  10. Golden PL, Pollack GM (2003) Blood–brain barrier efflux transport. J Pharm Sci 92:1739–1753

    Article  CAS  Google Scholar 

  11. Abraham MH, Chadha HS, Mitchell RC, Bonding H (1994) Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci 83:1257–1268

    Article  CAS  Google Scholar 

  12. Wahl M, Schilling L, Unterberg A, Baethmann A (1993) Mediators of vascular and parenchymal mechanisms in secondary brain damage. In: Mechanisms of Secondary Brain Damage. Springer, New York, pp 64–72

    Chapter  Google Scholar 

  13. Gururangan S, Friedman HS (2002) Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clin N Am 12:583–597

    Article  Google Scholar 

  14. Menei P, Capelle L, Guyotat J et al (2005) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56:242–248

    Article  Google Scholar 

  15. DiMeco F, Li KW, Tyler BM et al (2002) Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 97:1173–1178

    Article  CAS  Google Scholar 

  16. Westphal M, Ram Z, Riddle V et al (2006) Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 148:269–275

    Article  CAS  Google Scholar 

  17. Cosolo WC, Martinello P, Louis WJ, Christophidis N (1989) Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Phys Regul Integr Comp Phys 256:R443–R447

    CAS  Google Scholar 

  18. Cloughesy TF, Black KL (1995) Pharmacological blood-brain barrier modification for selective drug delivery. J Neuro-Oncol 26:125–132

    Article  CAS  Google Scholar 

  19. Greig NH, Genka S, Daly EM et al (1990) Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol 25:311–319

    Article  CAS  Google Scholar 

  20. Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:S5

    Article  Google Scholar 

  21. Zhao Y, Yue P, Tao T, CHEN Q (2007) Drug brain distribution following intranasal administration of Huperzine a in situ gel in rats 3. Acta Pharmacol Sin 28:273–278

    Article  CAS  Google Scholar 

  22. Sukriti S, Tauseef M, Yazbeck P, Mehta D (2014) Mechanisms regulating endothelial permeability. Pulm Circ 4:535–551

    Article  Google Scholar 

  23. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–1380

    Article  CAS  Google Scholar 

  24. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392. https://doi.org/10.1021/bc100070g

    Article  CAS  Google Scholar 

  25. Brigger I, Morizet J, Aubert G et al (2002) Poly (ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 303:928–936

    Article  CAS  Google Scholar 

  26. Recht L, Torres CO, Smith TW et al (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72:941–945

    Article  CAS  Google Scholar 

  27. Dixit S, Novak T, Miller K et al (2015) Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale 7:1782–1790

    Article  CAS  Google Scholar 

  28. Lu F, Pang Z, Zhao J et al (2017) Angiopep-2-conjugated poly (ethylene glycol)-co-poly (ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine 12:2117

    Article  CAS  Google Scholar 

  29. Hefnawy A, Khalil IA, El-Sherbiny IM (2017) Facile development of nanocomplex-in-nanoparticles for enhanced loading and selective delivery of doxorubicin to brain. Nanomedicine 12:2737–2761

    Article  CAS  Google Scholar 

  30. Roque ACA, Bicho A, Batalha IL et al (2009) Biocompatible and bioactive gum Arabic coated iron oxide magnetic nanoparticles. J Biotechnol 144:313–320

    Article  CAS  Google Scholar 

  31. Chertok B, David AE, Yang VC (2010) Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 31:6317–6324

    Article  CAS  Google Scholar 

  32. Roque ACA, Wilson OC Jr (2008) Adsorption of gum Arabic on bioceramic nanoparticles. Mater Sci Eng C 28:443–447

    Article  CAS  Google Scholar 

  33. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV (2009) Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30:3986–3995

    Article  CAS  Google Scholar 

  34. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV (2003) Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 92:49–67

    Article  CAS  Google Scholar 

  35. Bolotin EM, Cohen R, Bar LK et al (1994) Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 4:455–479

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Materials Science, University of Science and Technology (UST), Zewail City of Science and Technology, Giza, Egypt

    Amr Hefnawy & Ibrahim M. El-Sherbiny

Authors
  1. Amr Hefnawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim M. El-Sherbiny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim M. El-Sherbiny .

Editor information

Editors and Affiliations

  1. CONRAD / Eastern Virginia Medical School, Arlington, VA, USA

    Vivek Agrahari

  2. Department of Neurosurgery and Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA

    Anthony Kim

  3. Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

    Vibhuti Agrahari

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Hefnawy, A., El-Sherbiny, I.M. (2021). Passive and Active Targeting of Brain Tumors. In: Agrahari, V., Kim, A., Agrahari, V. (eds) Nanotherapy for Brain Tumor Drug Delivery. Neuromethods, vol 163. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1052-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-1052-7_2

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-1051-0

  • Online ISBN: 978-1-0716-1052-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation